Radiopharmaceutical company Telix Pharmaceuticals Ltd. received a U.S. FDA refusal to file letter for its BLA seeking approval of renal cancer imaging agent TLX250-CDx (89Zr-DFO-girentuximab) for clear cell renal cell carcinoma (ccRCC).
The U.S. FDA accepted Telix Pharmaceuticals Ltd.’s new drug application for TLX-007-CDx, a new cold kit for preparing prostate-specific membrane antigen-PET imaging for prostate cancer.
The U.S. FDA accepted Telix Pharmaceuticals Ltd.’s new drug application for TLX-007-CDx, a new cold kit for preparing prostate-specific membrane antigen-PET imaging for prostate cancer.
Researchers from Shandong University and affiliated organizations reported the discovery and preclinical characterization of novel 68Ga-labeled PSMA-targeting tracers for the diagnosis of prostate cancer.
Researchers from BC Cancer Research Institute (Provincial Health Services Authority) and the University of British Columbia have presented the discovery and preclinical characterization of [68Ga]LW-02050, a 68Ga-labeled hydroxamate derivative of SB3.
Asieris Pharmaceuticals Co. Ltd. has described indole phthalocyanine compounds acting as fluorescence imaging agents with high contrast reported to be useful for the diagnosis of bladder cancer.
The U.S. FDA granted fast track designation to Telix Pharmaceutical Ltd.’s TLX101-CDx for glioma imaging as the firm prepares to file its NDA in the first half of 2024, a Telix spokesperson told BioWorld.
Researchers from Massachusetts General Hospital recently detailed the discovery of [11C]SY-08, a new PET radiotracer that detects aggregated α-synuclein (α-Syn) fibrils in individuals with neurological disorders such as Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies.
